Read why Roivant Sciences founder and CEO Vivek Ramaswamy has been portrayed by some as being the next wizard of Wall Street for “conjuring drug companies from thin air.”
As Republicans attempt to recover from their face-plant on repealing and replacing Obamacare, policymakers are grappling with how to address the growing problem of healthcare provider consolidation, which appears to be raising costs and undermining competition.
Many of the company founders I’ve spoken with often admit that had they known how difficult starting a biopharmaceutical company would be, they would have likely never embarked on the journey in the first place.
Regulatory agencies today are looking for Phase 3 trials to demonstrate a reduction in mortality as well as greater patient mobility. Unfortunately, Phase 3 trials also cost a lot of money to run, making them a challenge for small biotech firms.
Andreas Koester, MD, Ph.D., global head, R&D operations innovation at Janssen, discusses how the company is attempting to make patient data available to participants while a clinical trial is underway.
It’s a sobering trend for the pharmaceutical industry. The counterfeit medicines market is growing at twice the rate of the market for legitimate prescription drugs. So what can be done?
Read all the exclusive content — including who our CMO award winners are this year — in the 2017 CMO Awards Special Edition.
This is the third article in a series on biosimilars. The first two pieces layout the background of the biosimilar market to date and the challenges shaping the market. This article sets out to explain how biosimilar companies are achieving differentiation and what it will take to establish market share.
Without change, China’s current healthcare system will become unaffordable. The latest round of reforms are aimed at ensuring sustainability by reducing costs. The reforms, if implemented effectively, will have a significant impact on companies operating in the sub-sectors of medical devices, pharmaceuticals, and healthcare services.
This article provides details of the different players that exist in the complex biosimilar market, all of which have different characteristics, histories, reasons for entry, internal capabilities and resources available to support their programs.
President Trump promised to take action to streamline the federal government. Within just a few days of taking office, he launched his deregulatory agenda, and he has now issued several executive orders that build on each other. How the concept will be implemented and by whom will continue to evolve with the addition of key staff.
Since the late nineteenth century, it has been well-known that individuals can vary widely in their responses to the same medication. Yet, accurately predicting and addressing the effects of that variability during drug development has continued to bedevil researchers, drug sponsors, and regulators.
Being the head of any Big Pharma is bound to test an executive’s work-life balance. But when that Big Pharma is headquartered in Australia, and the company prides itself on being a “global operation,” maintaining any kind of work-life balance is a formidable task. “I’m not the poster child for how to strive for work-life balance,” admits Paul Perreault, CEO and managing director of CSL.
In 2002 Liz Lewis joined Takeda where she is currently chief counsel and head of patient advocacy at Takeda Oncology. Lewis sat down with me to share how she helped enhance Takeda Oncology’s patient advocacy organization.
The executive-level participation for Life Science Leader magazine's signature 2017 Outlook issue had an overwhelming. This year’s feature article involved 13 executive life science leaders! In part four of this series, which is a supplement to the feature magazine article, we pose the question, “Looking even further ahead, what is your vision for how the global biopharmaceutical industry might look in the year 2027?”
I’ve been thinking, if you were going to name someone to be the biopharmaceutical industry CEO of the year, who would it be? But even more important than the who is the why. What criteria would you use? I’ve been looking through a bunch of articles that list top influencers for our industry, and the criterion for inclusion seems pretty subjective. There are media outlets that employ a variety of objective measures (i.e., company performance). And while perhaps better than a completely subjective approach, we all know that having great sales performance doesn’t necessarily make you a great leader. One of the best methodologies I have seen for naming a top CEO was done by the Harvard Business Review in 2015. It included financial data (weighted at 80 percent) and a measurement of a company’s environmental, social, and governance (ESG) performance (weighted at 20 percent).
Not long ago I had the opportunity to go to an invitation-only event attended by some of the biopharmaceutical industry’s biggest thought leaders. At the time, Repeal and Replace of the Affordable Care Act (ACA) was a priority for the new administration. But now that it has failed, you might be wondering what else should folks in biopharma be paying attention to?